IN2012DN03219A - - Google Patents
Info
- Publication number
- IN2012DN03219A IN2012DN03219A IN3219DEN2012A IN2012DN03219A IN 2012DN03219 A IN2012DN03219 A IN 2012DN03219A IN 3219DEN2012 A IN3219DEN2012 A IN 3219DEN2012A IN 2012DN03219 A IN2012DN03219 A IN 2012DN03219A
- Authority
- IN
- India
- Prior art keywords
- formulations
- stable
- hyaluronidase
- immunoglobulin
- months
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27704509P | 2009-09-17 | 2009-09-17 | |
| PCT/US2010/002545 WO2011034604A2 (en) | 2009-09-17 | 2010-09-16 | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03219A true IN2012DN03219A (de) | 2015-10-23 |
Family
ID=43034406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3219DEN2012 IN2012DN03219A (de) | 2009-09-17 | 2010-09-16 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9084743B2 (de) |
| EP (1) | EP2477603B1 (de) |
| JP (1) | JP5734985B2 (de) |
| KR (1) | KR101441768B1 (de) |
| CN (1) | CN102655853B (de) |
| AU (1) | AU2010296017C1 (de) |
| BR (1) | BR112012005890B1 (de) |
| CA (1) | CA2774053C (de) |
| CO (1) | CO6460736A2 (de) |
| DK (1) | DK2477603T3 (de) |
| EA (1) | EA026112B1 (de) |
| ES (1) | ES2578478T3 (de) |
| HR (1) | HRP20160530T1 (de) |
| HU (1) | HUE028832T2 (de) |
| IN (1) | IN2012DN03219A (de) |
| MX (1) | MX2012003282A (de) |
| PL (1) | PL2477603T3 (de) |
| PT (1) | PT2477603E (de) |
| WO (1) | WO2011034604A2 (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130135986A (ko) | 2003-03-05 | 2013-12-11 | 할로자임, 아이엔씨 | 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물 |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| FI4269578T3 (fi) | 2008-03-06 | 2024-06-07 | Halozyme Inc | Liukoisen hyaluronidaasin suurimittainen tuotanto |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| KR101647932B1 (ko) | 2008-04-14 | 2016-08-11 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| US20120172299A1 (en) * | 2008-09-23 | 2012-07-05 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
| IN2012DN03219A (de) | 2009-09-17 | 2015-10-23 | Baxter Healthcare Sa | |
| EP2531218B1 (de) | 2010-02-04 | 2018-12-12 | CSL Behring AG | Immunglobulinzubereitung |
| US10420923B1 (en) | 2010-08-10 | 2019-09-24 | Amiram Katz | Method and device for intrathecal administering of immunoglobulin |
| WO2012174478A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| MX342735B (es) | 2011-10-24 | 2016-10-07 | Halozyme Inc | Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. |
| WO2013063290A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| ES2609582T3 (es) | 2011-12-30 | 2017-04-21 | Halozyme, Inc. | Variantes de polipéptidos de PH20, formulaciones y usos de los mismos |
| US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
| CN108796028A (zh) * | 2012-07-24 | 2018-11-13 | 日产化学工业株式会社 | 培养基组合物以及使用所述组合物培养细胞或组织的方法 |
| US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
| CN112999245A (zh) * | 2012-09-26 | 2021-06-22 | 骨治疗公司 | 包含溶剂/去污剂处理过的血浆(s/d血浆)的制剂及其用途 |
| KR101454646B1 (ko) * | 2012-11-05 | 2014-10-27 | (주)한국비엠아이 | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 |
| US9700486B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| LT2994160T (lt) | 2013-05-06 | 2019-08-26 | Baxalta Incorporated | Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2016029220A1 (en) * | 2014-08-22 | 2016-02-25 | Nectagen, Inc. | Affinity proteins and uses thereof |
| EP3191187B1 (de) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Kombinationstherapie mit anti-cd38-antikörpern |
| CN106999510B (zh) | 2014-10-01 | 2021-04-30 | 伊格尔生物制品有限公司 | 含有粘度降低剂的多糖和核酸制剂 |
| CA2968915A1 (en) | 2014-12-03 | 2016-06-09 | Csl Behring Ag | Pharmaceutical product with increased stability comprising immunoglobulins |
| TWI721959B (zh) | 2014-12-04 | 2021-03-21 | 美商健生生物科技公司 | 治療急性骨髓性白血病之抗ｃｄ３８抗體 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| MA46315A (fr) | 2015-06-22 | 2019-08-07 | Janssen Biotech Inc | Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| MA43187B1 (fr) * | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP4570825A3 (de) * | 2016-04-29 | 2025-09-03 | Inovio Pharmaceuticals, Inc. | In-vivo-verwendung von chondroitinase und/oder hyaluronidase zur verbesserung der abgabe eines wirkstoffs |
| WO2018002181A1 (en) * | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| AU2018253931A1 (en) * | 2017-04-21 | 2019-11-21 | Csl Behring Ag | Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy |
| WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| WO2019110823A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| US20210047390A1 (en) * | 2018-01-31 | 2021-02-18 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against respiratory syncytial virus |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| CN118773171B (zh) | 2018-07-25 | 2026-03-13 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US20200206132A1 (en) * | 2018-12-31 | 2020-07-02 | Incube Labs, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| SG11202110512WA (en) | 2019-03-25 | 2021-10-28 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| CN110728044B (zh) * | 2019-09-30 | 2022-08-02 | 哈尔滨工程大学 | 一种针对于活塞环槽内气体压力状态的集成计算方法 |
| LT4087875T (lt) | 2020-01-08 | 2024-10-25 | argenx BV | Žmogaus neonatalinių fc receptorių (fcrn) antagonistai, skirti pūslinių ligų gydymui |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| KR102265730B1 (ko) * | 2020-11-06 | 2021-06-17 | 주식회사 본에스티스 | 피부 주름 개선 및 미백용 화장료 조성물 |
| IL302860A (en) * | 2020-11-17 | 2023-07-01 | Janssen Sciences Ireland Unlimited Co | Treatment or prevention of a disease or disorder |
| TW202320849A (zh) * | 2021-08-02 | 2023-06-01 | 比利時商阿根思公司 | 皮下用單位劑型 |
| CN118139636A (zh) * | 2021-09-14 | 2024-06-04 | 武田药品工业株式会社 | 使用透明质酸酶的经促进的浓缩抗体制剂的递送 |
| MX2024005173A (es) * | 2021-10-29 | 2024-05-29 | Alteogen Inc | Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco. |
| WO2023170680A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
| AU2023291786A1 (en) | 2022-06-15 | 2024-12-12 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
| CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
| JP2026501982A (ja) | 2022-12-22 | 2026-01-20 | ハロザイム，インコーポレイティド | 高容量投与のためのヒアルロニダーゼ酵素製剤 |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| AU2024274880A1 (en) | 2023-05-25 | 2026-01-15 | The Regents Of The University Of California | Methods of treating cancer |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966906A (en) | 1961-10-11 | 1976-06-29 | Behringwerke Aktiengesellschaft | Disaggregated gamma globulin and process for preparing it |
| US3869436A (en) | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5420124B2 (de) | 1974-01-16 | 1979-07-20 | ||
| CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| JPS5731623B2 (de) | 1975-02-19 | 1982-07-06 | ||
| US4126605A (en) | 1975-12-29 | 1978-11-21 | Plasmesco Ag | Process of improving the compatibility of gamma globulins |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4165370A (en) | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| US4124576A (en) | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| JPS5420124A (en) | 1977-07-14 | 1979-02-15 | Green Cross Corp:The | Preparation of gamma-globulin intravenous injection |
| US4186192A (en) | 1978-12-18 | 1980-01-29 | Cutter Laboratories, Inc. | Stabilized immune serum globulin |
| US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
| JPS5731623A (en) | 1980-07-30 | 1982-02-20 | Morishita Seiyaku Kk | Production of gamma-globulin for intravenous injection |
| US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| JPS57128635A (en) | 1981-01-30 | 1982-08-10 | Morishita Seiyaku Kk | Pharmaceutical preparation of gamma-globulin for venoclysis |
| US4396608A (en) | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| US4439421A (en) | 1982-08-30 | 1984-03-27 | Baxter Travenol Laboratories, Inc. | Stabilized gamma globulin concentrate |
| DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| JPH0669961B2 (ja) | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| JPH0662436B2 (ja) | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
| JP2547556B2 (ja) | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | ｒ−グロブリンの液状製剤 |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| AT402261B (de) | 1991-01-25 | 1997-03-25 | Immuno Ag | Komplex enthaltend den gerinnungsfaktor ix |
| JPH04346934A (ja) | 1991-05-24 | 1992-12-02 | Green Cross Corp:The | γ−グロブリンの液状製剤 |
| CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| EP0675201A1 (de) | 1994-03-31 | 1995-10-04 | Amgen Inc. | Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten |
| US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US5665069A (en) | 1996-07-19 | 1997-09-09 | Cumer; Patricia Lynn | Pressure-directed peribulbar anesthesia delivery device |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6123938A (en) | 1996-10-17 | 2000-09-26 | The Regents Of The University Of California | Human urinary hyaluronidase |
| US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| JP4270590B2 (ja) | 1997-03-19 | 2009-06-03 | 田辺三菱製薬株式会社 | 免疫グロブリン製剤 |
| GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| AT405739B (de) | 1997-09-19 | 1999-11-25 | Immuno Ag | Verfahren zur reinigung von antithrombin iii |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6362254B2 (en) | 1998-03-12 | 2002-03-26 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| CN1314992A (zh) | 1998-07-03 | 2001-09-26 | 奈勒斯菲尔德控制有限公司 | 流体测量的方法和装置 |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
| EP1259562B1 (de) | 1999-12-22 | 2006-02-15 | Nektar Therapeutics Al, Corporation | Sterisch gehinderte derivate von wasserlöslichen polymeren |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US20030212021A1 (en) * | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| CA2408851C (en) | 2000-05-16 | 2011-07-12 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
| ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US6571605B2 (en) | 2001-01-19 | 2003-06-03 | Larry Keith Johnson | Constant-head soil permeameter for determining the hydraulic conductivity of earthen materials |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| MXPA04004336A (es) | 2001-11-07 | 2005-05-16 | Nektar Therapeutics Al Corp | Polimeros ramificados y sus conjugados. |
| JP2005510229A (ja) | 2001-11-28 | 2005-04-21 | ネオーズ テクノロジーズ， インコーポレイテッド | アミダーゼを用いる糖タンパク質のリモデリング |
| US7192468B2 (en) | 2002-04-15 | 2007-03-20 | Fluor Technologies Corporation | Configurations and method for improved gas removal |
| JP2004147535A (ja) | 2002-10-29 | 2004-05-27 | Japan Science & Technology Agency | ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物 |
| KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
| EP2218779A1 (de) | 2002-12-16 | 2010-08-18 | Halozyme, Inc. | Humanes Chondrotinaseglykoprotein (CHASEGP), Verfahren zu dessen Herstellung und pharmazeutische Zusammensetzungen, die dieses umfassen |
| CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| JP2004238392A (ja) | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
| DK2236154T3 (en) * | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| LT1596887T (lt) | 2003-02-26 | 2022-04-25 | Nektar Therapeutics | Polimero-faktoriaus viii fragmento konjugatai |
| KR20130135986A (ko) | 2003-03-05 | 2013-12-11 | 할로자임, 아이엔씨 | 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물 |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JP4346934B2 (ja) | 2003-03-25 | 2009-10-21 | 日本碍子株式会社 | セラミックス構造体の製造方法 |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| PT2644206T (pt) | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
| EP1532983A1 (de) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulinpräparationen mit erhöhter Stabilität |
| US7572613B2 (en) * | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
| ES2661032T3 (es) * | 2006-09-08 | 2018-03-27 | Abbvie Bahamas Ltd. | Proteínas de unión a interleucina-13 |
| WO2009037566A2 (en) * | 2007-06-19 | 2009-03-26 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
| FI4269578T3 (fi) * | 2008-03-06 | 2024-06-07 | Halozyme Inc | Liukoisen hyaluronidaasin suurimittainen tuotanto |
| TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| KR101647932B1 (ko) | 2008-04-14 | 2016-08-11 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| WO2009128918A1 (en) | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| SI3037529T1 (sl) | 2008-12-09 | 2019-06-28 | Halozyme, Inc. | Razširjeni topni polipeptidi PH20 in njihove uporabe |
| KR101464032B1 (ko) | 2009-05-27 | 2014-11-27 | 백스터 인터내셔널 인코포레이티드 | 피하 사용을 위한 고 농축 면역글로불린 제제의 제조 방법 |
| IN2012DN03219A (de) | 2009-09-17 | 2015-10-23 | Baxter Healthcare Sa | |
| US8796430B2 (en) * | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| AU2010202125B1 (en) * | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| MX348420B (es) * | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
| JP6055412B2 (ja) * | 2010-09-17 | 2016-12-27 | バクスアルタ ゲーエムベーハー | 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化 |
| ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| ES2609582T3 (es) | 2011-12-30 | 2017-04-21 | Halozyme, Inc. | Variantes de polipéptidos de PH20, formulaciones y usos de los mismos |
| BR112014024848A2 (pt) | 2012-04-04 | 2017-07-11 | Halozyme Inc | terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor |
-
2010
- 2010-09-16 IN IN3219DEN2012 patent/IN2012DN03219A/en unknown
- 2010-09-16 ES ES10760140.3T patent/ES2578478T3/es active Active
- 2010-09-16 US US12/807,991 patent/US9084743B2/en active Active
- 2010-09-16 CN CN201080051813.3A patent/CN102655853B/zh active Active
- 2010-09-16 BR BR112012005890-8A patent/BR112012005890B1/pt not_active IP Right Cessation
- 2010-09-16 CA CA2774053A patent/CA2774053C/en active Active
- 2010-09-16 MX MX2012003282A patent/MX2012003282A/es active IP Right Grant
- 2010-09-16 AU AU2010296017A patent/AU2010296017C1/en active Active
- 2010-09-16 PL PL10760140.3T patent/PL2477603T3/pl unknown
- 2010-09-16 JP JP2012529751A patent/JP5734985B2/ja active Active
- 2010-09-16 EP EP10760140.3A patent/EP2477603B1/de active Active
- 2010-09-16 KR KR1020127009795A patent/KR101441768B1/ko active Active
- 2010-09-16 HU HUE10760140A patent/HUE028832T2/en unknown
- 2010-09-16 PT PT107601403T patent/PT2477603E/pt unknown
- 2010-09-16 DK DK10760140.3T patent/DK2477603T3/en active
- 2010-09-16 HR HRP20160530TT patent/HRP20160530T1/hr unknown
- 2010-09-16 WO PCT/US2010/002545 patent/WO2011034604A2/en not_active Ceased
- 2010-09-16 EA EA201200490A patent/EA026112B1/ru unknown
-
2012
- 2012-04-12 CO CO12060153A patent/CO6460736A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2477603T3 (pl) | 2016-10-31 |
| US9084743B2 (en) | 2015-07-21 |
| CA2774053A1 (en) | 2011-03-24 |
| JP2013505237A (ja) | 2013-02-14 |
| EP2477603A2 (de) | 2012-07-25 |
| HK1173652A1 (zh) | 2013-05-24 |
| EP2477603B1 (de) | 2016-03-30 |
| CO6460736A2 (es) | 2012-06-15 |
| EA026112B1 (ru) | 2017-03-31 |
| MX2012003282A (es) | 2012-04-30 |
| CN102655853A (zh) | 2012-09-05 |
| BR112012005890B1 (pt) | 2023-01-17 |
| HRP20160530T1 (hr) | 2016-07-29 |
| EA201200490A1 (ru) | 2012-12-28 |
| ES2578478T3 (es) | 2016-07-27 |
| JP5734985B2 (ja) | 2015-06-17 |
| CA2774053C (en) | 2015-04-28 |
| CN102655853B (zh) | 2015-07-29 |
| WO2011034604A3 (en) | 2011-12-01 |
| HUE028832T2 (en) | 2017-01-30 |
| KR101441768B1 (ko) | 2014-09-17 |
| AU2010296017A1 (en) | 2012-05-03 |
| BR112012005890A2 (pt) | 2019-09-24 |
| AU2010296017B2 (en) | 2013-06-06 |
| KR20120105426A (ko) | 2012-09-25 |
| WO2011034604A9 (en) | 2012-01-19 |
| PT2477603E (pt) | 2016-06-16 |
| AU2010296017C1 (en) | 2013-09-19 |
| WO2011034604A2 (en) | 2011-03-24 |
| DK2477603T3 (en) | 2016-06-13 |
| US20110066111A1 (en) | 2011-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03219A (de) | ||
| PH12018501294A1 (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| MX2011010930A (es) | Modulacion de respuestas inflamatorias a través de factor xi. | |
| EP2603227A4 (de) | Verbesserte hämatopoetische stamm- und vorläuferzelltherapie | |
| BR112014031874A2 (pt) | método para preparar células-tronco em concentração elevada | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| NZ706296A (en) | Glucosylceramide synthase inhibitors | |
| GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
| MX2015000337A (es) | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. | |
| EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| IN2015DN02729A (de) | ||
| IN2014DN07483A (de) | ||
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
| MX2022008842A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
| PH12014500859A1 (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
| MX365464B (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| MX2015015200A (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. | |
| BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos | |
| AU2016204146A1 (en) | Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid | |
| IN2013MU02370A (de) | ||
| MD545Y (en) | Process for treating tomato seeds with low viability | |
| PL414890A1 (pl) | Środek aktywujący | |
| UA89523U (ru) | Способ хранения бактерий вида escherichia coli |